Human CD33 is a myeloid-restricted transmembrane protein of the sialic acid-binding Ig-like lectin (Siglec) family. While structural analysis predicts an inhibitory function, it remains unknown under which circumstances CD33 may operate as an inhibitory molecule. Here we show that treatment of human monocytes with anti-CD33 mAb induces the production of the proinflammatory cytokines IL-1b, TNF-a, and IL-8. However, decreased CD33 surface expression obtained by RNA interference using cognate small interfering RNA (siRNA) was specifically paralleled by spontaneous cytokine production. Similarly, sialic acid (CD33 ligand) removal from the monocyte surface by neuraminidase resulted in IL-1b up-regulation, while the addition of red blood cells or sialyllactosamine (but not lactosamine) reversed the effect of neuraminidase treatment, thus demonstrating the importance of ligand recognition by CD33 for repression of monocyte activation. Finally, inhibition of phosphoinositide 3-kinase (PI3K) dramatically enhanced the IL-1b response to anti-CD33 and neuraminidase, while inhibition of p38 mitogen-activated protein kinase (MAPK) abolished it. Simultaneous addition of both inhibitors resulted in low levels of IL-1b, suggesting that CD33 exerts an inhibitory role mediated by PI3K, while p38 MAPK signaling is required for IL-1b production. These data indicate that by controlling monocyte activation, CD33 is a key molecule in the inflammatory response, depending on the sialic acid microenvironment for its repressor activity.
Introduction
In humans, CD33 is a 67-kDa myeloid cell-specific type I transmembrane glycoprotein expressed at the surface of myeloid progenitors and mature monocytes, but it is lost in mature granulocytes [1] . Because of the selective pattern of CD33 expression, a humanized anti-CD33 mAb coupled to the anti-cancer agent calicheamicin has been proposed to treat relapsed CD33 + acute myeloid leukemia [2, 3] . CD33 functions as a lectin recognizing a2,3-and, more avidly, a2,6-linked sialic acid-bearing glycans [4, 5] . Its extracellular domain shares sequence similarities with the Siglec (sialic acid-binding Ig-like lectin) subgroup of the immunoglobulin superfamily, of which CD33 is a founding member together with sialoadhesin, CD22, and myelin-associated glycoprotein. Several additional Siglec family members have been identified through genome and functional analyses, each having a particular specificity in sialic acid binding and cell expression pattern [6] . Most of our knowledge on the function of Siglec on immune cells derives from studies on CD22. CD22 is a B cell-specific transmembrane glycoprotein containing immunoreceptor tyrosine-based inhibitory motifs (ITIM) and is known to primarily function as a negative regulator of B cell receptor signaling [7] [8] [9] [10] . It plays a role in B cell activation and antibody production during normal immune responses and in autoantibody-mediated autoimmune disorders [11] . The ligand binding activity of CD22 coupled to its ability to recruit the Src homology 2 domain-containing protein tyrosine phosphatase (SHP)-1 is critical for its negative regulatory function [9, 10] .
In view of the structural similarities between CD22 and CD33, it has been suggested that CD33 may function on cells of the innate immune system as an inhibitory molecule [6, 12] . The cytoplasmic tail of CD33 contains two putative tyrosine-based signaling motifs, both potential ITIM, but only the membrane-proximal motif exactly matches the consensus sequence. CD33 receptor engagement by anti-CD33 mAb induces tyrosine phosphorylation with recruitment of SHP-1 and SHP-2 [13, 14] and results in reduced calcium influx when human monocytes are activated by FccRI [14, 15] . Furthermore, anti-CD33 mAb reduces survival and prevents maturation of human monocytes into dendritic cells [16] . Similar findings have been obtained by engagement of human Siglec-7 (p75/AIRM), an inhibitory molecule expressed on monocytes and NK cells [17] . Of interest, the murine ortholog of CD33 lacks the two ITIM, and CD33-deficient mice are not distinctly different from wild-type mice [18] . Thus, the mouse model is not suitable for understanding the functions of CD33 in humans.
IL-1b, TNF-a, and IL-8 are potent immunoregulatory and critical proinflammatory mediators released by activated human monocytes in many circumstances, particularly in chronic inflammatory disorders. IL-8 is a CXC chemokine (CXCL8) mainly involved in polymorphonuclear phagocyte recruitment [19] . IL-1b and TNFa have similar and broad ranges of physiological effects in regulating local and systemic immune responses and are key factors implicated in inflammatory diseases such as rheumatoid arthritis [20] . In this context, we and others have demonstrated that contact-dependent monocyte activation by T cells is powerful in triggering the production of large amounts of proinflammatory cytokines [21] .
The aim of the present study was to assess whether CD33 is capable of negatively controlling the production of IL-1b, TNF-a, and IL-8 by human monocytes. We show that CD33 has constitutive repressor activity on monocytes due to interactions with sialic acid residues and that disruption of CD33 binding to sialic acid results in strong production of proinflammatory cytokines.
Results
Anti-CD33 mAb induces the production of proinflammatory cytokines in monocytes Engagement of CD33 on peripheral blood human monocytes by specific mAb resulted in the release of high levels of IL-1b, IL-8, and TNF-a (Fig. 1A) . These results were observed with all monocytes tested, regardless of the donor (n=25). The effect of specific antibody was dose-dependent and observed using two distinct anti-CD33 mAb belonging to two different IgG isotypes, IgG1 and IgG2a, but not with irrelevant IgG1 and IgG2a mAb. In addition, cytokine production mediated by anti-CD33 mAb was unaffected by the presence of polymyxin B, while LPS-induced responses were powerfully inhibited, ruling out endotoxin contamination of the anti-CD33 mAb (Fig. 1B) . Furthermore, CD33 engagement greatly enhanced IL-1b production when monocytes were activated by PMA or by contact with T cells (Fig. 1C) . Thus, CD33 engagement by mAb results in up-regulation of proinflammatory cytokine production by monocytes and enhances their response to activating stimuli.
CD33 gene silencing in monocytes results in up-regulation of proinflammatory cytokines
Up-regulation of proinflammatory cytokine production induced by anti-CD33 mAb may be due to either an agonist or a blocking activity of these antibodies. To distinguish between these two possibilities, we chose to down-regulate the spontaneous expression of CD33 on peripheral blood monocytes by RNA interference (RNAi) using small interfering RNA (siRNA) duplex technology. Silencing was monitored by cytofluorometry. The expression of CD33 was specifically and consistently reduced by cognate siRNA duplex by day 2, with maximal decrease at day 4 after transfection; no reduction was seen when nonspecific siRNA containing the inverted CD33 sequence was used ( Fig. 2A) . Cognate siRNA duplex did not affect the expression of other monocyte surface markers including CD11b and CD14, thus proving specificity ( Fig. 2A) . More importantly, the specific silencing of the CD33 gene was matched by enhanced spontaneous production of IL-1b, IL-8, and TNF-a, which reached levels 200% to 400% higher than those induced by inverted CD33 siRNA used as nonspecific control (Fig. 2B) . Since the decrease in surface expression was accompanied by enhanced proinflammatory cytokine production, these results demonstrate that CD33 represses activation of human monocytes and indicate that the anti-CD33 mAb we used (Fig. 1A) indeed blocked CD33 function. 
Down-regulation of CD33 expression in activated monocytes
We next investigated whether activation of fresh monocytes results in modulation of CD33 expression. Substantial down-regulation of CD33 expression was observed when monocytes were activated by T cell contact, FccR cross-linking, PMA and, to a lesser extent, LPS (Fig. 3A) , while under similar conditions CD11b (used as control) was up-regulated ( Fig. 3B) . Thus, CD33 down-regulation accompanies monocyte activation and, owing to diminished repression, may amplify the cascade of events initiated by activation.
Sialic acids are required for CD33-mediated repressor activity
CD33 is an adhesion molecule that recognizes sialylated motifs [4, 5], so we explored whether the interaction of CD33 with its ligand plays a role in its repressor activity. We reasoned that if this were the case, a decrease in sialic acid content in the monocyte microenvironment would result in CD33 losing its repressor activity. Indeed, desialilated (neuraminidase-treated) monocytes showed a marked up-regulation of IL-1b production ( Fig. 4A ), which greatly exceeded the enhanced production induced by anti-CD33 mAb (p<0.001) (Fig. 4A) . IL-1b production was prevented by heatinactivation of neuraminidase enzymatic activity and was unaffected by the presence of polymyxin B (Fig. 4A) . Thus, sialic acid residues present on the surface of monocytes act in cis as ligands for CD33 and are required for its repressor activity. We then examined whether other cell types expressing sialic acid can act in trans as donors of CD33 ligands. To this aim, increasing numbers of red blood cells (RBC) were added to desialilated monocytes and the production of IL-1b assessed. Intact RBC, but not desialilated RBC, efficiently reduced the production of IL-1b in a dose-dependent manner (Fig. 4B ). As expected, intact RBC did not affect IL-1b production induced by anti-CD33 mAb (Fig. 4B) . We further assessed the role of sialic acid requirement for CD33-mediated repressor activity by using a mixture of a2,3-and a2,6-sialyllactosamine, considered to be the specific structures recognized by CD33 [4, 5] . Significant dose-dependent neutralization of the neuraminidase-induced IL-1b production was observed in the presence of sialyllactosamine but not in the presence of similar amounts of lactosamine, thus confirming the need for sialic acid as a key factor in the negative regulation of monocytes treated with neuraminidase (Fig. 4C ).
Distinct roles of phosphoinositide 3-kinase (PI3K) and p38 MAP K in CD33-initiated signal transduction
To elucidate the potential signaling pathways underlying the repressor activity of CD33, we used a battery of pharmacological agents aimed at specific inhibition of distinct pathways. The IL-1b response (protein and steady-state mRNA levels) to anti-CD33 or to neuraminidase was dramatically enhanced by treatment of monocytes with the PI3K-specific inhibitor LY294002, and it was abolished after treatment with the p38 MAPK inhibitor SB203580 (p<0.001). Moreover, addition of p38 MAPK inhibitor dominantly abrogated the enhancement of IL-1b production following PI3K inhibition (Fig. 5A-D) . Consistent with these findings, phosphorylation of p38 was observed in monocytes activated by anti-CD33 (Fig. 5E) or neuraminidase (not shown), and p38 phosphorylation was abrogated by SB203580. Interestingly, we could not observe an increase in p38 phosphorylation when monocytes were preincubated with LY294002, thus indicating that IL-1b enhancement induced by PI3K was not operating directly on p38 MAPK. Remarkably, no modulation of IL-1b mRNA or CD33 surface expression was observed when the PI3K and MAPK inhibitors were used in the absence of monocyte activation by anti-CD33 or neuraminidase (data not shown). The selective usage of PI3K and p38 MAPK in intracellular signaling initiated by CD33 was Fig. 3 . CD33 surface expression is down-regulated in monocytes activated by T cell contact, PMA, FccR cross-linking, and LPS. Peripheral blood monocytes were cultured in medium alone (resting monocytes, shaded area), with T cell membranes (equivalent T cell to monocyte ratio 1:1, dark line in B), with PMA (1 ng/ml, gray line in B), in wells coated with human IgG (20 lg/ml, to induce FccR cross-linking), or with LPS (100 ng/ml) for 48 h, and expression levels of CD33 (A) and CD11b (B) were assessed by cytofluorometry.
stressed by the lack of significant effects when ocadaic acid (an inhibitor of the phosphatase PP2A), rapamycin (a FRAP/mTOR inhibitor), Ro-31-8425 (a general PKC inhibitor), or PD098069 (an MEK/ERK inhibitor) were used (data not shown). Altogether, these observations indicate that responses to anti-CD33 and neuraminidase involve the same signaling pathways and argue for an inhibitory role of PI3K independent of p38 MAPK action.
Discussion
In the present study, we provide for the first time evidence for the role of CD33 in controlling the production of proinflammatory cytokines by human monocytes through active repression. We show that: (i) reduction of CD33 at the cell surface of monocytes by RNAi-mediated silencing or CD33 blockade by antibody results in the enhanced secretion of IL-1b, IL-8, and TNFa. (ii) Monocyte activation induced by T cell contact, FccR engagement, PMA, or LPS is specifically accompanied by the decreased surface expression of CD33. (iii) Constitutive CD33 repressor activity is directly dependent on interaction with its ligand sialic acid, and sialic acid residues on monocyte surface are functionally sufficient. (iv) PI3K and p38 MAPK are involved in transducing signals initiated by CD33 and resulting in the repression of IL-1b production. These results are in agreement with and substantiate previous assumptions on the negative regulatory role of CD33 in humans and improve our understanding of the function of the Siglec transmembrane proteins [6, 12] .
According to our observations, monocyte activation is directly controlled by sialic acid microenvironment through interactions with CD33. More precisely, the disruption of CD33 binding to its ligand correlates with an activated state of monocytes and strongly argues for a constitutive repressor activity mediated by CD33. Consistent with this hypothesis, all the experimental approaches resulting in decreased levels of CD33 at the cell surface (blockade by mAb, RNAi) or in decreased levels of sialic acid (neuraminidase treatment) provided uniform evidence of monocyte activation. Similarly, monocyte activation by stimuli such as T cell contact, FccR engagement, PMA and, to a lesser extent, LPS resulted in decreased levels of CD33, while RBC and synthetic a2,3-and a2,6-sialyl ligands were solely effective on neuraminidase-treated monocytes. Of interest, neuraminidase treatment resulted in the highest levels of monocyte activation observed, and RBC could reduce this activation by only approximately 60%. These data indicate that CD33 interacts with sialic acid preferentially in cis rather than in trans, possibly due to the small size of CD33, an observation consistent with previous results obtained in binding assays of CD33 expressed on COS cells and CD22 on B cells [4, 22] . Alternatively, molecules other than CD33 expressed on human monocytes may operate as repressors by interacting with sialic acid residues; these could include human Siglec-5, -7, -9, and -10 with specificity for 2,3 and 2,6 glycosidic linkages of sialic acid. It should be stressed, however, that human Siglec-7, which is the most likely candidate expressed on monocytes, preferentially recognizes a2,8-sialyl ligands [6] . Nonetheless, our data, in agreement with previous analyses, stress the point that sialic acid is an essential molecular target of self-recognition that plays an important role in downregulating inflammatory responses by engaging inhibitory receptors [12] . Along the same line of thought, the lack of sialic acid expression on most microorganisms and in some cases on virally infected or transformed cells may be recognized as a missing self-signal and favor an immune response [23] .
Based on results obtained with RNAi, the presence of CD33 at the cell surface is crucial to maintain monocytes in the resting state. Partial removal of CD33 from the surface was sufficient to induce substantial monocyte activation, implying that the mechanism underlying CD33-mediated repression is potent and finely tuned. Whether the partial CD33 down-regulation generated by siRNA was the result of incomplete silencing due to long turnover of the molecule or to partial efficacy of the targeted sequence of the CD33 gene remains to be examined. Of interest, CD33 down-regulation induced by siRNA and by monocyte activation upon PMA stimulation or T cell contact was similar in magnitude. Decreased levels of CD33 expression may be instrumental in preventing undesirable repression when monocytes need to be activated. This mechanism may act jointly with other mechanisms, such as the abrogation of the lectin function by 9-O-acetylation of sialic acid residues or by simultaneous expression of sialyltransferases that specifically catalyze the production of ligand, as described for CD22 [22] .
Pharmacological inhibition of p38 MAPK in monocytes activated by anti-CD33 mAb or neuraminidase treatment resulted in a dramatic decrease in IL-1b production concomitantly with reduced p38 phosphorylation. Consistently with these findings, p38 MAPK was shown to regulate the transcription of IL-1b mRNA by modulating the activity of transcription factors, particularly NF-jB [24] . Thus, we propose that the p38 signaling cascade is crucial to IL-1b expression. Of clear interest, the enhanced IL-1b production observed in anti-CD33 mAb-or neuraminidase-activated monocytes when PI3K is inhibited by LY294002 indicates an inhibitory activity exerted by PI3K on IL-1b production. Others have shown that in murine DC, PI3K negatively regulates IL-12 synthesis by suppressing p38 MAPK activity, a crucial positive regulator of IL-12 production [25] . In our experimental settings, however, we could not demonstrate a direct effect of PI3K on the levels of p38 phosphorylation. Thus, it may be hypothesized that PI3K exerts its inhibitory function either downstream of the p38 MAPK pathway or independently by directly or indirectly inducing a repressor element acting on the IL1b gene. Although it still remains unknown how PI3K suppresses IL-1b production, published data may lead to the following hypothesis. SHP-1 is known to negatively control PI3K activity through its p85 subunit [26] . The intracytoplasmic tail of CD33 contains ITIM sites that recruit SHP-1. Furthermore, in the absence of its ligand, CD33 was shown to become highly phosphorylated [13, 27] . Thus, it is possible that CD33 phosphorylation induced by disrupted binding to sialic acid results in recruitment of SHP-1 phosphatase, which in turn inhibits PI3K activity, finally releasing the negative regulation of IL-1b.
Contrasting with the effects of the PI3K and p38 inhibitors, ocadaic acid (an inhibitor of the phosphatase PP2A), rapamycin (a FRAP/mTOR inhibitor), Ro-31-8425 (a PKC inhibitor), and PD098069 (an MEK/ ERK inhibitor) did not shown significant effects in our experimental settings. Others have shown that the cytoplasmic tail of CD33 can be phosphorylated on serine residues by PKC, an effect inhibited by staurosporine, and that this can regulate sialic acid binding activity in transfected cells [27] . However, the functional impact in cell signaling was not investigated. Our results with the Ro-31-8425 PKC inhibitor suggest that the negative regulatory activity of CD33 is independent of serine phosphorylation. Differences in potency and specificity between staurosporine and Ro-31-8425 could explain the discrepancies between our results and those of others.
In conclusion, the bulk of our results is consistent with the concept of a constitutive repressor activity mediated by CD33 on monocytes, and it lends support to the hypothesis that the default setting for monocytes is, as suggested by others [28] , an activated state. Upon binding to sialic acid, CD33 may, in concert with other molecules, wire monocytes, preventing them from releasing proinflammatory mediators. On the other hand, by sensing decreased levels of sialic acid in the microenvironment (missing self), CD33 will induce IL1b production by monocytes, thus participating in the delivery of alarm signals, a scenario recently hypothesized by Medzhitov and Janeway [29] .
Materials and methods

Reagents and antibodies
Polymyxin B sulfate, phorbol myristate acetate (PMA), Clostridium perfringens neuraminidase, sialyllactosamine (80% NeuAca-2,3Galb1,4; 20% NeuAca-2,6Galb1,4), lactosamine, and bovine serum albumin were from Sigma (St. Louis, MO). Sheep RBC were from BioMØrieux (Lyon, France). PI3K inhibitor LY294002, p38 MAPK inhibitor SB203580, PKC inhibitor Ro-31-8425, ocadaic acid, and rapamycin were obtained from Calbiochem (San Diego, CA). Anti-human CD33 mAb clone WM53 (IgG1) was from Serotec (Oxford, UK), and clone CD33-4D3 (IgG2b) was obtained from Caltag Laboratories (Burlingame, CA).
Isolation of human monocytes
Monocytes were isolated from fresh peripheral blood of normal healthy volunteers obtained from the blood transfusion center of the Geneva University Hospital upon clearance by the ethical committee. Briefly, peripheral blood mononuclear cells isolated over a Ficoll-Paque (Pharmacia, Uppsala, Sweden) density gradient were incubated at 50Â10 6 cells/ml in RPMI 1640 medium containing 10% heat-inactivated FCS, 50 U/ml penicillin, 50 lg/ml streptomycin, 5 mM non-essential amino acids (complete medium) (all from Invitrogen, Paisley, UK) for 40 min at 4 C under rotation, leading to monocyte aggregation. Pellets of aggregated monocytes were separated by a gradient of FCS and further depleted of T and NK cells by overnight rosetting with sheep RBC [30] . Monocyte preparations routinely consisted of >85% CD14 + cells, <1.5% CD3 + cells, <1% CD19 + cells as assessed by flow cytometry.
Polymyxin B (5 lg/ml) was present throughout the whole isolation procedure [31] . To prevent activation upon adhesion, monocytes were purified in polypropylene tubes. Each experiment was performed with cells from single donors.
T cell membrane preparation
The human T lymphoma cell line HUT-78 was activated by the addition of 1 lg/ml PHA and 5 ng/ml PMA for 16 h. Plasma cell membranes were prepared as effectors of T cell contact as described [30] . Briefly, cell suspensions were kept on ice and sonicated with five 5-s bursts of 40 W each, nuclei were pelleted by centrifugation at 4,000Âg for 15 min, and the supernatants were centrifuged at 100,000Âg for 45 min at 4 C. Membrane pellets were suspended in RPMI 1640
containing 10% FCS and 5 mM iodoacetamide and frozen at -70 C until use [30] .
Monocyte activation and measurement of cytokines
Freshly isolated monocytes were cultured in flat-bottom 96-well tissue culture trays at 50Â10 3 cells per well in complete RPMI medium containing polymyxin B (5 lg/ml), unless otherwise specified, in the presence of the indicated stimuli. For activation by FccR engagement, the wells were coated overnight with 20 lg/ml protein G-purified normal human IgG in PBS and were washed three times with PBS before adding the cells. In some experiments, monocytes were preincubated with specific cell-permeable inhibitors for 30 min prior to addition of the indicated stimuli. After 48 h of culture, the production of IL-1b (Immunotech, Marseille, France), TNF-a, and IL-8 (Biosource, Nivelles, Belgium) was assessed in culture supernatants by ELISA. The sensitivity threshold was 2 pg/ml for the three cytokine assays.
Western blot analysis
Freshly isolated monocytes were starved by overnight culture in the absence of serum in polypropylene tubes (Falcon). Cells were harvested, suspended at 4Â10 6 cells in 1 ml medium, and cultured at 37 C for various amounts of time with or without anti-CD33 (1 lg/tube) or 1% neuraminidase upon preincubation for 30 min with specific inhibitors. After incubation, monocytes were washed twice with ice-cold PBS and total cell lysates prepared. For Western blot analysis, 20 to 40 lg of protein was separated by SDS-PAGE and transferred to Hybond-ECL membrane (Amersham). The blots were probed with anti-p38 (Cell Signaling) or anti-phospho-p38 (Thr 180/ Tyr 182, New England Biolabs) antibodies and revealed with secondary horseradish peroxidase-conjugated goat anti-rabbit antibody (Dako) as described [32] .
siRNA preparation and transfection siRNA preparations and RNAi were performed according to published methods [33, 34] . Duplexes of 21-nucleotide siRNA with two 3 0 -overhanging TT were chemically synthesized with purity >97%, (Dharmacon Inc., Boulder, CO). The CD33 siRNA sequence targeting CD33 (GenBank; Acc. No. M23197) corresponded to the coding region 241-261 relative to the first nucleotide of the start codon. As a nonspecific control, a duplex with the inverted CD33 sequence (invCD33) was synthesized under the same conditions. Transfection of siRNA for targeting the endogenous CD33 gene in freshly purified monocytes was performed using Oligofectamine (Invitrogen) according to supplier's instructions. Briefly, for each well of a 24-well plate, 0.84 lg siRNA duplex (3 ll of 20 lM) was mixed in a tube with 50 ll Opti-MEM (Invitrogen). In another tube, 3 ll Oligofectamine reagent was mixed in 12 ll Opti-MEM and incubated at room temperature for 7 to 10 min. The solutions were then combined and mixed by inversion and incubated for another 20 min at room temperature. siRNA-Oligofectamine (68 ll) was added to cultured cells (0.6Â10 6 cells in 500 ll RPMI culture medium supplemented with 10% FCS without antibiotics). The expression of the targeted gene was monitored by FACS, and cytokine production was determined by ELISA at different time points.
Flow cytometric analysis
Two-color staining of monocytes was performed using: PElabeled CD33-4D3 mouse anti-CD33, biotin-labeled ICRF44 mouse anti-CD11b/Mac1, FITC-labeled M5E2 mouse anti-CD14, and PE-labeled streptavidin. Cells were analyzed with a FACSCalibur (BD Bioscience, San Diego, CA)
RNA extraction and RNase protection assay
Total RNA was prepared from monocytes by lysing the cells with TRIzol reagent (Invitrogen). Expression of IL-1b and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was analyzed with the RiboQuant RNase protection assay using the hck-2 multiprobe template set (BD Bioscience). The hybridized RNA was digested with RNase and resolved on denaturing polyacrylamide gels according to the RiboQuant protocol. Signal intensity was determined densitometrically upon autoradiography using ImageQuant software (Molecular Dynamics).
Statistical analysis
Experimental data were compared by two-tailed Student's t test using Excel software (Microsoft Corporation, Bellevue, WA). A p value of <0.05 was considered significant.
